PSMA-targeted dendrimer as an efficient anticancer drug delivery vehicle for prostate cancer-Reference-Cited by-同舟云学术

PSMA-targeted dendrimer as an efficient anticancer drug delivery vehicle for prostate cancer

Published:2024 Issue:11 Volume:16 Page:5634-5652
ISSN:2040-3364
Container-title:Nanoscale
language:en
Short-container-title:Nanoscale

Author:

Dhull Anubhav¹,Wei Jing²,Pulukuri Anunay James¹,Rani Anu¹,Sharma Rishi¹^ORCID,Mesbahi Nooshin¹,Yoon Hosog¹,Savoy Emily A.¹,Xaivong Vi Sylvia¹,Goody Kenneth John¹,Berkman Clifford E.¹,Wu Boyang Jason²,Sharma Anjali¹^ORCID

Affiliation:

1. Department of Chemistry, College of Arts and Sciences, Washington State University, Pullman, WA, USA

2. Department of Pharmaceutical Sciences, College of Pharmacy and Pharmaceutical Sciences, Washington State University, Spokane, WA, USA

Abstract

We present PD-CTT1298 nanoplatform as a versatile approach for selective systemic delivery of high payloads of potent chemotherapeutics to PSMA (+) prostate cancer, where dose related systemic side-effects are a major concern.

Funder

National Institutes of Health

Publisher

Royal Society of Chemistry (RSC)

Link

http://pubs.rsc.org/en/content/articlepdf/2024/NR/D3NR06520K

Reference67 articles.

1. Trends in Prostate Cancer in the United States

2. Metastatic patterns of prostate cancer: An autopsy study of 1,589 patients

3. Preclinical efficacy of growth hormone-releasing hormone antagonists for androgen-dependent and castration-resistant human prostate cancer

4. Androgens regulate prostate cancer cell growth via an AMPK-PGC-1α-mediated metabolic switch

5. Hormonal Therapy of Prostatic Cancer

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. PSMA-Targeted 2-Deoxyglucose-Based Dendrimer Nanomedicine for the Treatment of Prostate Cancer;Biomacromolecules;2024-08-21